Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AC Immune S.A.
(NQ:
ACIU
)
3.190
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AC Immune S.A.
< Previous
1
2
3
4
5
Next >
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
AC Immune SA
Via
GlobeNewswire
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023
March 14, 2024
ACIU stock results show that AC Immune beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
March 14, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
February 22, 2024
From
AC Immune SA
Via
GlobeNewswire
Why Shares of AC Immune Jumped This Week
June 30, 2023
The FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.
Via
The Motley Fool
Why AC Immune Stock Skyrocketed Today
June 27, 2023
AC Immune SA (NASDAQ: ACIU) shares surged Tuesday after the company received FDA Fast Track Designation for its anti-amyloid-beta active immunotherapy, ACI-24.060,
Via
Benzinga
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
January 22, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
January 03, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial
December 15, 2023
AC Immune SA's (NASDAQ: ACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with...
Via
Benzinga
AC Immune Announces Pricing of Underwritten Offering of Common Shares
December 15, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
December 15, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
December 01, 2023
From
AC Immune SA
Via
GlobeNewswire
Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth
November 28, 2023
Although growth penny stocks present extraordinary risks, if you exercise meticulous care, these ideas might be worth a shot.
Via
InvestorPlace
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
November 21, 2023
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this
Via
Benzinga
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
November 07, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 03, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
November 02, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
October 27, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
October 17, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
October 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
September 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 04, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
July 28, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune SA Appoints New Chief Medical Officer
July 26, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
July 03, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
June 27, 2023
From
AC Immune SA
Via
GlobeNewswire
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 27, 2023
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
Via
Benzinga
AC Immune Holds Annual General Meeting of Shareholders
June 23, 2023
From
AC Immune SA
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
June 01, 2023
It's time to start the day with a breakdown of the biggest pre-market stock movers that traders need to know about for Thursday morning!
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 05, 2023
Good morning! We're diving into the biggest pre-market stock movers traders will want to keep an eye on for Friday morning!
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.